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Abstract: Autoimmunity forms the basis of many rheumatological diseases, and may contribute not only to the classical 
clinical manifestations but also to the complications. Many of the autoimmune rheumatological diseases, including rheu-
matoid arthritis and systemic lupus erythematosus are associated with an excess cardiovascular morbidity and mortality. 
Much of this excess cardiovascular risk can be attributed to atherosclerotic disease. Atherosclerosis is a complex patho-
logical process, with dyslipidaemia and inflammation fundamental to all stages of plaque evolution. The heightened in-
flammatory state seen in conjunction with many rheumatological diseases may accelerate plaque formation, both through 
direct effects on the arterial wall and indirectly through inflammation-mediated alterations in the lipid profile. Alongside 
these factors, antibodies produced as part of the autoimmune nature of these conditions may lead to alterations in the lipid 
profile and promote atherosclerosis. In this review, we discuss the association between several of the rheumatological 
autoimmune diseases and dyslipidaemia, and the potential cardiovascular impact this may confer.  
Keywords: Autoimmune disease, dyslipidaemia, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, pri-
mary sjogrens syndrome, anti-phospholipid syndrome. 
INTRODUCTION 
  The complexity and diversity of many rheumatological 
conditions is often attributed to their underlying autoimmune 
nature. Autoimmunity contributes to the clinical manifesta-
tions, as well as complications of disease and response to 
treatment. Rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE) have been found to associate with an 
increased risk for cardiovascular disease (CVD) [1-3], result-
ing in a significantly shortened lifespan. As a consequence, 
much speculation and research has focused on the role of 
both traditional and novel, disease specific, risk factors. In 
the general population, dyslipidaemia has been shown to be 
one of the strongest predictors of CVD, with elevated levels 
of low-density lipoproteins (LDL) forming the primary 
treatment target according to national guidelines [4]. In this 
review we discuss the association between several of the 
autoimmune rheumatological conditions (RA, SLE, primary 
antiphospholipid sysndrome (primary APS), systemic sclero-
sis (SSc), and primary Sjogrens syndrome (PSS)) and 
dyslipidaemia, and the potential impact this has on cardio-
vascular risk, in particular atherosclerotic plaque formation.  
ATHEROSCLEROTIC PLAQUE FORMATION: THE 
ROLE OF LIPIDS AND INFLAMMATION 
  Coronary artery disease develops due to the formation 
and rupture of atherosclerotic plaques. The term atheroscle-
rosis covers a spectrum of disease ranging from endothelial  
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dysfunction and fatty streak development, through to the 
formation and rupture of a mature plaque. The development 
of atherosclerotic plaques is complex. Inflammation is fun-
damental to all stages of atherosclerotic plaque [5], with an 
intense bi-directional interaction occurring between lipids 
and inflammation. Rheumatological autoimmune diseases 
are associated with a heightened inflammatory state in vary-
ing degrees, thus these processes may be accelerated. 
  Endothelial dysfunction is the initiating step in plaque 
development [6]. Healthy endothelium exerts a number of 
vasoprotective effects such as vasodilation, suppression of 
smooth muscle cell growth and inhibition of inflammatory 
responses, thereby helping to protect against atherosclerosis. 
Nitric oxide mediates many of these effects by inhibiting 
platelet aggregation and LDL oxidation, as well as opposing 
the effects of endothelium-derived vasoconstrictors [7]. En-
dothelial damage occurs when the fine balance between 
vasoconstrictive and vasodilatory pathways is disrupted. 
Although endothelial dysfunction is likely to be a multi-
factorial process, the major cardiovascular risk factors such 
as hypercholesterolaemia, hypertension, diabetes and smok-
ing have been implicated via their ability to increase the pro-
duction of reactive oxygen species [8]. It is postulated that 
the increase in reactive oxygen species may in turn reduce 
endothelial nitric oxide (NO) availability [9, 10]. Multiple 
lipid abnormalities have been associated with endothelial 
dysfunction. Hypercholesterolaemia has been shown to 
cause focal activation of the endothelium in medium and 
large arteries and has been associated with an increased 
number of monocytes entering the intima [11]. High levels 
of oxidised LDL (oxLDL) may down regulate endothelial 
NO synthase (eNOS), thus reducing available NO and re-
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ing triglycerides (TGs) may also damage the endothelium via 
their oxidative charge and result in disruption of the normal 
NO pathway [13, 14]. Studies into the effects of lipoprotein 
(a) (Lp(a)) have shown elevated levels to be inversely corre-
lated with small artery compliance and NO production [15, 
16]. High levels of systemic inflammation may also disrupt 
endothelial homeostasis via  the NO pathway, by reducing 
the expression of eNOS and increasing the expression of 
inducible NO synthase producing a net excess of NO [17]. 
Too much nitric oxide can also be deleterious to the endothe-
lium, thus a very fine balance of NO needs to be maintained 
in order to preserve and protect the endothelium [18]. 
  Due to the increased permeability of the dysfunctional 
endothelium, excess LDL infiltrates the artery wall and is 
retained in the intima by matrix components. LDL then un-
dergoes modification and oxidation, inducing the endothelial 
cells to express leukocyte adhesion molecules [19] and initi-
ating an inflammatory response in the artery wall [20]. The 
contribution of oxLDL particles to the development of athe-
rosclerosis is summarised in Fig. (1). 
  The first cells attracted to the activated endothelium are 
platelets [21]. They adhere via glycoproteins on their sur-
face, triggering further endothelial activation resulting in 
leukocyte infiltration [22]. Once in the sub-endothelial 
space, monocytes are transformed to macrophages and sub-
sequent incorporation of LDL via endocytosis by scavenger 
receptors (CD36 and others) differentiates them further into 
foam cells. The accumulation of foam cells, smooth muscle 
cells and T cells results in the formation of a fatty streak 
(Fig. 2a), the earliest recognisable lesion of atherosclerosis 
[23].  
  Fatty streaks can progress to form intermediate and ad-
vanced lesions (Fig. 2b), by amplification of the processes 
involved in formation of fatty streaks. The advanced lesions 
tend to form a protective fibrous cap that walls off the lesion 
from the lumen. Advanced plaques have a lipid-rich necrotic 
core containing an abundance of tissue factor, which plays a 
vital role in thrombus formation upon plaque rupture [24]. 
  Plaque instability and rupture occurs due to uneven thin-
ning or erosion of the fibrous cap. Destabilisation and degra-
dation of the fibrous cap results from the production of in-
flammatory cytokines, proteases, radicals, coagulation fac-
tors and vasoactive molecules, from activated macrophages, 
T cells and mast cells [25]. The above events lead to plaque 
rupture, exposing the contents of the core of the plaque to the 
circulating blood and subsequent activation of the clotting 
cascade. As the thrombus forms and enlarges, the arterial 
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RHEUMATOID ARTHRITIS 
  RA affects approximately 1% of the adult population in 
the United Kingdom [26]. RA predominately affects the 
synovial joints resulting in joint pain, swelling and stiffness, 
but can also produce an array of clinical manifestations as 
part of the systemic nature of the disease, ranging from con-
stitutional symptoms to organ involvement. Uncontrolled 
inflammation can confer a large personal, socio-economic, 
and psychosocial burden as a consequence of significant 
joint destruction and deformity.  
  RA patients have a reduced life expectancy and increased 
mortality rates compared to the general population [1, 3], 
with CVD accounting for approximately half of all RA 
deaths [27]. A recent meta-analysis has shown that the risk 
of death from CVD is almost 50% higher in RA patients 
compared to healthy controls [28]. Although CVD in RA can 
present in many guises (e.g. congestive heart failure, myo-
cardial infarction (MI) and pericarditis), it is those with an 
underlying ischaemic pathology that pose the greatest mor-
tality risk, as a consequence of atherosclerotic plaque forma-
tion [29-31]. Despite this, atherosclerotic disease remains 
under-diagnosed in RA due to an often atypical or silent 
presentation [32]. Although the mechanisms responsible for 
this phenomenon still need to be elucidated, differences in 
atherosclerotic plaque structure may be responsible. Athero-
sclerotic plaques of RA patients differ morphologically to 
those observed in the general population, with less histologi-
cal evidence of atherosclerosis but far greater plaque insta-
bility [33]. Such differences may also offer a potential ex-
planation for the higher fatality rates associated with MI in 
RA and the increases seen in post MI complication rates 
[34]. 
  Atherosclerosis in RA may be enhanced through several 
pathways. Traditional cardiovascular risk factors such as 
hypertension [35, 36] and obesity [37-39] may occur more 
frequently in RA or be modified through disease specific 
mechanisms. In addition, novel risk factors such as systemic 
inflammation, hyperhomocysteinaemia [40] and activation of 
the coagulation pathway [41] may further escalate athero-
sclerotic plaque formation. In fact, the impact of systemic 
inflammation on CVD is so great it has now been recognised 
as an independent cardiovascular risk factor in the general 
population [42, 43]. Although there is a degree of interplay 
between all of the risk factors, systemic inflammation ap-
pears to be fundamental to virtually all. Furthermore, RA 
patients may be genetically predisposed to the development 
of atherosclerosis and myocardial infarction [44, 45]. 
  Dyslipidaemia is highly prevalent in RA affecting be-
tween 55-65% of patients [46, 47] and can manifest in RA 
patients with both early [48] and advanced disease [49]. One 
retrospective study on 1078 blood donors has suggested that 
the lipid profile may be altered prior to the onset on RA [50]. 
This study demonstrated that the 79 blood donors who later 
developed RA had significantly higher total cholesterol 
(TC), triglyceride (TG), apolipoprotein B (apoB) levels, and 
lower high density lipoprotein (HDL) levels up to ten years 
prior to the onset of RA compared to matched controls. This 
suggests that alterations in the lipid profile may render peo-
ple more susceptible to the future development of RA [51] or 
that RA patients are genetically predisposed to the develop-
ment of RA related dyslipidaemia or that the transcription of 
these genes is altered by persistent inflammation.  
  Although dyslipidaemia in RA may be partially governed 
by a genetic predisposition, it is also influenced by an array 
of other factors including disease activity [52], reduced 
physical activity secondary to pain and disability [53], and 
drug therapy [54, 55]. In untreated RA the lipid profile is 
characterised by suppression of HDL and TC levels [51, 56, 
57]. At first glance this appears to produce a less atherogenic 
profile, however, HDL levels fall disproportionately more 
compared to TC levels resulting in an increased atherogenic 
index (TC:HDL ratio) [48, 56, 58]. The largest study to 
compare the lipid profiles of untreated RA patients to a con-
trol group is the National Health and Nutrition Examination 
Survey (NHANES III) [54]. This study included 104 patients 
who were naïve to disease modifying anti-rheumatic drugs 
(DMARDs) and glucocorticoids (GCs). It confirmed a sig-
nificant fall in HDL and apolipoprotein A-I (apoAI) levels 
but failed to demonstrate any significant changes in other 
lipid levels. Current data exploring the effects of heightened 
disease activity on TG and low density lipoprotein (LDL) 
levels is conflicting with some studies reporting a positive 
association [56] and others a negative association [59, 60]. 
These discrepancies may be a consequence of limitations of 
study design, including small study size, differences in base-
line characteristics, and incomplete adjustment for con-
founders. 
  For many years, apolipoproteins have been recognised as 
potential markers for CVD in the general population [61]. 
This is rather unsurprising, as apolipoproteins are found in 
conjunction with lipid particles (e.g. Apo-AI with HDL and 
Apo-B100 with LDL). However, emerging evidence now 
indicates a superiority of measuring apolipoproteins as CVD 
risk factors, rather than their lipid counterpart (e.g. ApoB 
rather than LDL) [62]. In RA, Apo-AI levels decrease [48, 
52, 54, 63], mirroring the supression in HDL observed in 
active RA. Although, Apo-B levels have also been reported 
to be reduced with high levels of inflammation [64] this is to 
a lesser degree than Apo-AI levels [48, 52, 64].  
  For many years individual lipid levels have formed the 
basis of CVD risk stratification algorithms [4, 65]. However, 
the use of lipid and apolipoprotein ratios is gaining popular-
ity as they have been shown to confer a greater predictive 
value of first myocardial infarction than individual lipid lev-
els in the general population [66, 67]. The lipid ratios shown 
to be useful in risk stratification, include TC:HDL ratio [68], 
LDL:HDL ratio [69] and ApoB: ApoA1 ratio [70]. All three 
lipid ratios have been reported to increase in active RA [48, 
56]. In addition, lipid ratios have been considered as an at-
tractive alternative method of risk stratification in RA as 
they may overcome the inflammatory mediated fluctuations 
in individual lipid parameters [71].  
  Lipoprotein (a) (Lp(a)), is an LDL particle that is bound 
to apolipoprotein (a), by a disulphide bond with Apo-B100. 
Current evidence suggests Lp(a) is a key factor in the devel-
opment of atherosclerosis [72, 73]. The structure of Lp(a) 
may mechanistically contribute to atherosclerotic plaque 
formation, through its structural similaririties with plasmino-
gen. Lp(a) competes with plasminogen for its binding site, 
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hibitor –1 (PAI-1), with the net effect of enhancing plaque 
thrombosis [74]. In addition, Lp(a) has been shown to inter-
act with other established cardiovascular risk factors [75], 
including lipid parameters (HDL and LDL) [76]. In RA, sev-
eral studies have demonstrated a significant increase in Lp(a) 
levels [48, 54, 56, 77, 78], which in the majority of studies 
appears to shadow changes in LDL [48, 54, 56]. Although 
inflammation may partially control these changes in Lp(a), 
genetic factors may also contribute [79]. Apolipoprotein (a) 
has several phenotypic variations, due to allelic differences. 
A recent study has demonstrated that RA patients have a 
higher frequency of the S3 allele compared to healthy con-
trols (70% vs 39.5%) [79]. The presence of the S3 allele   
associates with a lower molecular weight of Apo(a) [80]. 
Furthermore, there is an inverse association between the   
molecular weight of Apo(a) and Lp(a) levels [81], thus   
potentially accounting for the increased Lp(a) levels   
observed in RA.  
  Further, intricate changes in lipid metabolism have been 
described in RA. High levels of oxidative stress can occur in 
conjunction with the chronic inflammatory burden of RA 
[66]. Lipid particles (in particular LDL) exposed to this envi-
ronment both within the synovial fluid and the plasma of RA 
patients are susceptible to oxidative modification [82, 83]. 
Once oxidised, the LDL particles exhibit enhanced pro-
atherogenic properties, through their ability to more readily 
infiltrate the arterial wall, form foam cells and initiate a   
localised inflammatory response.  
  Lipid/lipoprotein particles are not uniform and in healthy 
individuals are found in a range of sizes and densities. Such 
diversity is crucial for maintaining the normal pathways of 
lipid metabolism such as reverse cholesterol transport. How-
ever, these structural differences also dictate the atherogenic-
ity of each of the particles. Small dense LDL particles 
(LDL3) are more prone to oxidation and more readily able to 
infiltrate the arterial wall than their larger counterparts [84], 
whereas smaller HDL particles (HDL2) are more successful 
in performing reverse cholesterol transport and thus confer 
greater cardio-protection [85]. In RA, the limited available 
data appears to suggests that RA patients have a more pro-
atherogenic lipoprotein subfraction profile with higher levels 
of small dense LDL particles and lower levels of smaller 
HDL particles [86]. Alongside this, the balance of pro-
atherogenic/anti-atherogenic HDL may be further disrupted 
through suppression of enzymes including paraoxonase 1 
(PON) [87].  
  In summary, although we have a basic understanding of 
the effects of RA on the standard lipid profile (TC, LDL, TG 
and HDL levels) (Fig. 3), our understanding of dyslipidae-
mia in RA remains far from complete. Further large-scale 
studies are required to investigate the changes in 
lipid/lipoprotein structure and function and to establish the 
relative contribution of dyslipidaemia in its entirety to CVD 
in RA.  
SYSTEMIC LUPUS ERYTHEMATOSUS 
  Systemic lupus erythematosus (SLE) is a multisystem 
autoimmune disease that predominately affects premeno-
pausal females, with a peak age of onset between 20-30 
years. The condition can manifest with a broad spectrum of 
clinical signs and symptoms, ranging from relatively minor 
symptoms such as arthralgia to life-threatening organ in-
volvement. SLE has a relapsing remitting course, often re-
sulting in acute ‘flares’ characterised by a dramatic worsen-
ing of clinical symptoms, a heightened inflammatory re-
sponse and elevated auto-antibody levels.  
  SLE confers a massive CVD risk, which is far greater 
than described in other autoimmune diseases. Patients with a 
disease duration greater than 5 years have been reported to 
have 52 times greater risk of suffering a myocardial infarc-
tion than matched controls [2]. In fact, the processes under-
lying atherosclerosis are so advanced that subclincal athero-











Fig. (3). The main mechanisms contributing to dyslipidaemia and atherosclerosis in rheumatoid arthritis. IL-6: Interleukin-6, TNF: 
Tumour necrosis factor, CRP: C reactive protein, ROS: Reactive oxygen species, OxLDL: oxidised low-density lipoproteins, TC: total cho-
lesterol, HDL: High-density lipoproteins, LDL: low-density lipoproteins, ApoB:ApoA: apolipoproteinB: apolipoproteinA ratio, TC:HDL: 
total cholesterol: high-desnity lipoprotein ratio. 68    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Toms et al. 
[88]. Thus, it is unsurprising that SLE has now been identi-
fied as an independent risk factor for the development of 
endothelial dysfunction, the earliest vascular change in the 
process of atherosclerotic plaque formation [89]. It is now 
clear that although traditional risk factors, including dyslipi-
daemia may be more frequent in SLE these alone do not 
fully account for the excess cardiovascular morbidity and 
mortality [90]. Several disease specific factors have been 
implicated including inflammation, oxidative stress and the 
presence of anti-phospholipid antibodies [91, 92].  
  The dyslipidaemia seen in conjunction with SLE is more 
typical of that described in the general population in relation 
to CVD, with elevations in TG, LDL, TC and ApoB and a 
parallel fall in HDL levels [93]. Although the alterations in 
the lipid profile appear to be exacerbated by active disease, 
significant changes have been observed in patients with inac-
tive disease [94, 95], thus reflecting that factors other than 
inflammation may be at play (Fig. 4). Although the lipid 
profile seen in conjunction with active SLE (elevations in 
TC and LDL levels) appears to differ from that seen in active 
RA, there are also similarities (Table 1). Firstly, inflamma-
tory mediators such as CRP and ESR have been shown to 
suppress HDL levels and increase TG levels [96]. Secondly, 
other markers of disease activity including the systemic lu-
pus erythematosus disease activity index (SLEDAI) [94], 
C3d (a specific serological marker of lupus activity) levels 
[93], anti-double stranded DNA (dsDNA) levels [97]  and 
levels of inflammatory cytokines have been found to associ-
ate with lipid levels [98, 99]. One potential inflammation-
mediated mechanism that is thought to control some of the 
lipid alterations seen in SLE, is reduced activity of the en-
zyme lipoprotein lipase (LPL) [100], which may be gov-
erned by circulating inflammatory mediators (e.g. tumour 
necrosis factor and interleukin-6 (IL-6) [101], and antibodies 
directed against LPL (anti-LPL) [102]. LPL is responsible 
for the catabolism of chylomicrons and very low density 
lipoproteins (VLDL), thus suppression of LPL activity re-
sults in an accumulation of TG-rich particles [100]. The 
presence of cytokines including TNF- and IL-6 also trig-
gers hepatic production of CRP, which may further exacer-
bate HDL suppression. The high levels of circulating IL-6 
have been shown to inversely correlate with HDL levels. 
  High levels of systemic inflammation found in conjunc-
tion with SLE result in an increased burden of oxidative 
stress [103]. Increased oxidative stress can trigger a broad 
range of pro-atherogenic lipid modifications, including the 
formation of oxidised LDL (oxLDL), conversion of anti-
inflammatory HDL into pro-inflammatory HDL [104], and 
altering the function of key enzymes involved in lipid me-
tabolism and function [93]. The oxidation of LDL is particu-
larly interesting in SLE, as oxidation affects not only the 
lipid component of the lipoprotein but also components such 
as cardiolipin. Antibodies directed against oxidised cardi-
olipin (anti-phospolipid (aPL) antibodies) are increased in a 
proportion of SLE patients, predominately those exhibiting 
features of co-existant anti-phospholipid syndrome (APS) 
[105]. There are three aPL antibodies found in SLE 1) Lupus 
anticoagulant 2) anti-cardiolipin antibodies and 3) antibodies 
to  2  glycoprotein [105]. The presence of aPL antibodies 
confers an increased thrombotic risk in SLE [106], thus athe-
rosclerotic plaque rupture often has devastating implications 
due to vessel occlusion as a consequence of massive throm-
bus formation. The presence of IgG anti-cardiolipin antibod-
ies have also been associated with low levels of HDL and 
apolipoprotein A-1, thus further escalating CVD risk [107]. 
  SLE patients have high levels of antibodies against 
oxLDL, which may accelerate the uptake of LDL into the 
endothelial wall [108]. In addition, there is expanding evi-
dence that antibodies against oxLDL may cross-react with 
IgM and IgG anticardiolipin antibodies [108, 109], thus fur-
ther escalating CVD risk. Of particular interest oxLDL forms 
complexes with 2-glycoprotein I, which have been shown 
to amplify arterial thrombosis in patients with APS [110], 
and this may also be a pro-atherogenic mechanism in SLE 











Fig. (4). The main mechanisms contributing to dyslipidaemia and atherosclerosis in systemic lupus erythematosus. HDL: High-
density lipoprotein, ApoA1: apolipoprotein A1, APL Abs: anti-phospholipid antibodies, DsDNA: double stranded DNA, TG:triglycerides, 
LDL: low-density lipoproteins, TC: total cholesterol. Dyslipidaemia in Rheumatological Autoimmune Diseases  The Open Cardiovascular Medicine Journal, 2011, Volume 5    69 
  Several studies have investigated the lipoprotein subfrac-
tion profile in SLE, however, the impact of such changes on 
the development of subclinical atherosclerotic plaque forma-
tion and cardiovascular events remains to be established [93, 
111, 112]. The first study determined the LDL lipoprotein 
subfraction profile in 53 patients with SLE and 53 age and 
sex matched healthy controls, using the method of disc poly-
acrylamide gel electrophoresis [93]. SLE patients had in-
creased levels of small dense LDL subfractions, which were 
found to associate with high levels of oxidative stress and 
elevated CRP levels. Two further studies adopted the method 
of nuclear magnetic resonance (NMR) spectroscopy, allow-
ing quantification of both HDL and LDL subfractions [111, 
112]. The study by Hua et al., examined lipoprotein subfrac-
tions in 26 female SLE patients with a history of CVD 
(myocardial infarction, angina, thromoembolic stroke, or 
intermittent claudication), 26 age matched SLE patients 
without CVD and 26 age and sex matched controls [112]. 
This study demonstrated that SLE patients with a history of 
CVD had higher levels of small dense LDL than the healthy 
control population, however the same was not found for SLE 
patients without CVD. Lower levels of the small ‘cardio-
protective’ HDL subfractions were found in SLE patients 
(with and without CVD) compared to healthy controls. 
Chung  et al. also performed lipoprotein subclassification 
using NMR spectroscopy in 105 SLE patients (without a 
history of CVD) and 77 healthy controls [111]. The levels of 
small dense LDL did not significantly differ between SLE 
patients and controls and were not found to associate with 
coronary calcification. The differences observed in the lipo-
protein subfraction profile between these studies can be at-
tributed to differences in baseline demographics, the under-
lying CVD risk, drug therapy and methodology, as well as 
small study size. Further longitudinal studies are required to 
elucidate the role (if any) of lipoprotein subfractions to CVD 
in SLE. 
  A further two studies have focused on HDL subfractions 
[113, 114]. Both have demonstrated an atherogenic profile 
with increased levels of HDL3 and reduced levels of HDL2 
compared to healthy controls. 
  Lp(a) levels have been shown to be substantially in-
creased in SLE patients with studies reporting them to be 
almost double those seen in matched control populations 
[115-118]. This appears to be independent of the effects of 
disease activity, thromobotic events, the presence of aPL 
antibodies and glucocorticoid use [115]. Furthermore, SLE 
patients with a history of vascular disease have been found to 
have higher Lp(a) levels than SLE patients without a history 
of vascular disease [117, 119], thus indicating a causative 
role. Unfortunately, all studies to date are limited by the 
small sample size and cross-sectional design, thus making it 
impossible to draw conclusions regarding the impact of 
Lp(a) on CVD in SLE. Similar to the findings in RA, genetic 
factors are major determinants of elevated Lp(a) levels in 
SLE, with only the small apolipoprotein (a) phenotypes 
found to significantly predict Lp(a) levels in SLE [118]. 
  Data regarding changes in apolipoprotein levels and their 
relative contribution to CVD in SLE is sparse. One study 
comparing the lipid profile in 53 premenopausal SLE pa-
tients to 45 healthy controls reported significant elevations in 
both ApoA1 and apoB levels, with apoB levels found to as-
sociate with the presence of proteinuria [120]. A further 
study involving 46 SLE patients and 30 matched controls 
reported conflicting findings, with similar ApoA1 levels ob-
served in both groups [113]. The effects of treatment with 
glucocorticoids on apoplipoprotein levels also remains a 
matter of some debate, with one study demonstrating no 
change in ApoA1 levels [113] and another demonstrating an 
increase in apoA1 levels [121]. To date there have been no 
studies assessing the predictive value of apolipoproteins in 
CVD risk stratification.  
ANTI-PHOSPHOLIPID SYNDROME  
  The Antiphospholipid syndrome (APS) is characterised 
by a combination of arterial and venous thrombosis, recur-
rent miscarriages, and thrombocytopenia. Although APS is 
most commonly found as an overlap syndrome with SLE, it 
is also recognised as an independent clinical entity (primary 
APS) [122].  
  To date, there is much speculation as to whether primary 
APS patients are at greater risk of atherosclerotic plaque 
formation than the general population. Some of this uncer-
tainty stems from the significant limitations of the available 
study data, such as small study size and poor methodology 
[123], but may also be attributed to the lack of evidence to 
support a role of APL antibodies in atherothrombosis forma-
tion in non-SLE patients with MI [124, 125]. However, sev-
eral studies on primary APS patients have demonstrated sub-
clinical vascular changes consistent with endothelial dys-
Table 1.  A Summary of the Classical Lipid/Lipoprotein Profile in Autoimmune Rheumatological Conditions 
 TC  HDL  LDL  TG  Lp(a)  oxLDL  TC:HDL LDL:HDL  ApoB:ApoA1 
RA     ?  ?           
SLE                   
APS                   
PSS                   
SSc                   
RA: rheumatoid arthritis, SLE: systemic lupus eythematosus, APS: anti-phospholipid syndrome, PSS: primary sjogrens syndrome, SSc: systemic sclerosis, TC: total cholesterol, 
HDL: high density lipoproteins, LDL: low density lipoproteins, TG: triglycerides, Lp(a): lipoprotein (a), oxLDL: oxidised low density lipoproteins, TC:HDL: total cholesterol:high 
density lipoprotein ratio, LDL:HDL: low density lipoprotein:high density lipoprotein ratio, ApoB: ApoA1: apolipoprotein B: apolipoprotein A1 ratio.  = no change,  = de-
creased levels,  = increased levels, ? = conflicting data = no data. 70    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Toms et al. 
function and early atherosclerotic plaque formation including 
impaired flow mediated dilatation and increased carotid in-
tima-media thickness [126-128], respectively. Unfortunately, 
there is a lack of direct epidemiological evidence supporting 
a higher CVD morbidity or mortality in primary APS. 
  In line with a relative lack of available information on 
CVD in primary APS, data on dyslipidaemia in primary APS 
is also sparse. No studies have specifically been designed to 
assess dyslipidaemia in primary APS, however, a few small 
studies have commented on the lipid profile [128, 129]. The 
first study to comment on the lipid profile in primary APS, 
did not find any significant differences between TC, HDL, 
LDL, TG, ApoA1, ApoB, or Lp(a) levels compared to 
healthy controls [128]. A second study by Medina et al. 
[129] has reported conflicting findings with a significant 
increase in TG levels in patients with primary APS com-
pared to healthy controls. These differences can be explained 
by differences in study size, baseline demographics, inclu-
sion/exclusion criteria and auto-antibody status. Based on 
these studies alone we are unable to get a true representation 
of the extent of dyslipidaemia in primary APS (if any) and 
the impact this may have on CVD, thus further studies are 
required to address this. 
SJOGRENS SYNDROME 
  Primary Sjogren’s syndrome (PSS) is characterised by 
chronic inflammation of exocrine glands, resulting in ocular 
and oral dryness. Although a systemic disease, the inflamma-
tion associated with the condition is much less than that seen 
with RA or SLE. The prevalence of CVD in PSS remains to 
be established. However, examination of the carotid intima-
media thickness of patients with PSS compared to controls 
has demonstrated a higher prevalence of subclinical athero-
sclerosis (PSS 49% vs controls 11%) [130]. In this study, the 
presence of anti-SSA antibodies and leucopenia, but not al-
terations in the lipid profile, were found to associate with 
subclincal atherosclerosis. 
  Two investigators have specifically examined the lipid 
profile in PSS in relation to inflammation and autoantibody 
status. The first study conducted by Lodde et al. compared 
serum lipid profiles in 44 patients with PSS to 12 control 
patients with oral dryness failing to fulfil the diagnostic cri-
teria for PSS [131]. This demonstrated significantly lower 
TC and HDL levels in patients with PSS. Other lipid pa-
rameters, including lipid ratios (LDL, TG, TC:HDL ratio and 
LDL:HDL ratio) were not different between patients and 
control subjects. The levels of TC and HDL in the PSS pa-
tients were not found to associate with inflammation (CRP 
or ESR), however both were found to associate with IgG 
levels. Alongside this, TC and HDL levels were found to 
significantly inversely correlate with anti-SSA and anti-SSB 
antibodies, respectively. A second small study (37 females 
with PSS and 35 age-matched female controls) confirmed a 
decrease in HDL levels in patients with PSS, but other lipid 
components did not significantly differ [132]. HDL levels 
did not associate with inflammation or auto-antibody status.  
  Although patients with PSS exhibit some alterations in 
the lipid profile that are typical of those seen in RA and SLE, 
including suppression of HDL levels, the mechanisms under-
lying this need to be examined in more detail. Inflammation 
appears to be an unlikely culprit due to a lack of association 
seen in these studies. However, due to the comparative low-
grade inflammation seen in PSS much larger scale studies 
and more sensitive methodology (high sensitivity CRP) may 
be required to provide the power to detect such a relation-
ship. 
SYSTEMIC SCLEROSIS 
  Systemic sclerosis (SSc) is a condition characterised by 
skin fibrosis that advances proximally from the distal ex-
tremities. In addition, patients with SSc can develop compli-
cations arising from organ involvement, including pulmo-
nary fibrosis, renal failure and vasculopathy. The vascular 
involvement in SSc has traditionally been thought to be due 
to microvascular disease [133, 134], however, evolving data 
suggests an increased prevalence of macrovascular disease 
as well [135]. Patients with SSc have a fourfold increase in 
mortality compared to the general population, with approxi-
mately a third of all deaths due to cardiovascular causes 
[136]. Although, peripheral vascular disease (PVD) has been 
reported to be almost 5 times higher amongst patients with 
SSc than the general population [137, 138], carotid intima-
media thickness (IMT), a marker of subclinical atherosclero-
sis, has been found not to differ significantly between cases 
and controls [139, 140]. Irrespective of these findings, stud-
ies have demonstrated evidence of increased endothelial dys-
function in SSc patients compared to controls, as measured 
by flow-mediated dilatation [140, 141]. In addition, endothe-
lial dysfunction has been shown to improve following endo-
thelin receptor blockade in SSc [142]. Markers of arterial 
stiffness such as pulse wave velocity and aortic augmenta-
tion index have also been shown to be higher in SSc patients 
than in a control population [141].  
   Dyslipidaemia and its contribution to vascular dis-
ease/endothelial dysfunction in SSc remains relatively un-
studied with only a handful of small studies attempting to 
address this [135, 139, 143]. The changes in the lipid profile 
in SSc appear to be subtle, with many of the conventional 
lipid parameters reported to remain unchanged and only a 
significant increase in TG levels being witnessed by some 
investigators [143, 144]. The hypertryglyceridaemia in SSc 
may be mediated through reduced LPL activity as a conse-
quence of the formation of anti-LPL antibodies [144]. How-
ever, when delving deeper it is apparent that further poten-
tially pro-atherogenic changes including enhanced oxidation 
of LDL [145] and increased Lp(a) levels [146] occur. In-
creased levels of circulating adhesion molecules have also 
been noted in SSc. Although these appear to occur in con-
junction with endothelial dysfunction [147, 148], to date no 
direct associations have been made between adhesion mole-
cules and atherosclerotic disease in SSc.  
  In summary, patients with SSc may have an increased 
risk of CVD, but this requires further clarification in large-
scale studies specifically designed to assess this. In addition 
SSc patients appear to harbour several alterations in the arte-
rial wall including increased arterial stiffness and endothelial 
dysfunction, however, the contribution of dyslipidaemia to 
such changes, if any, requires further investigation. 
DRUG THERAPY AND DYSLIPIDAEMIA 
  The management of many of the autoimmune rheuma-
tological conditions relies upon the use of immunosuppres-Dyslipidaemia in Rheumatological Autoimmune Diseases  The Open Cardiovascular Medicine Journal, 2011, Volume 5    71 
sive agents, which are broadly divided in to glucocorticoids 
(GCs), disease modifying anti-rheumatic drugs (DMARDs), 
and biologic agents (e.g. anti-TNF). However, the use of 
these agents differs significantly between conditions due to 
efficacy, drug licensing, and side effects. Many of these 
medications alter the lipid profile with the most widely re-
ported change being an elevation in HDL levels [49, 149-
151]. The most likely mechanism to account for such 
changes in the lipid profile is generic suppression of inflam-
mation. However, some medications have been shown to 
exert drug specific effects on the lipid profile. For example, 
Hydroxychloroquine (HCQ), a DMARD used in the man-
agement of RA and SLE, has been reported to produce a less 
atherogenic lipid profile by lowering TC, LDL and TG and 
increasing HDL levels [152, 153]. The advent of newer ‘po-
tent’ biologic agents offering rapid anti-inflammatory effects 
has sparked interest surrounding their effect on the lipid pro-
file. However, due to the contraindications of anti-TNF use 
in SLE patients, most of the data attempting to address this 
issue has been based in RA patients. The available data 
demonstrates an increase in TC and HDL levels, with out an 
overall change in the atherogenic index (TC:HDL) [151, 
154]. Thus again potentially reflecting a reversal of the pre-
viously inflammatory-mediated suppression of the lipid pro-
file. Despite these findings, very little data exists regarding 
the more intricate effects of these drugs on lipids, such as 
lipid subfractions, lipid modifications (e.g. LDL oxidation) 
and lipid function, and the impact that these may have on 
cardiovascular risk.  
CONCLUSION 
  Autoimmunity plays a major role in the development of 
dyslipidaemia and atherosclerotic plaque formation in many 
rheumatological conditions. The mechanisms underlying 
these changes include the interplay of inflammation and 
auto-antibody formation. Although the pattern of dyslipi-
daemia appears to differ between the autoimmune rheuma-
tological diseases outlined in this review, many of the under-
lying mechanisms are similar (Fig. 5). Thus treatment op-
tions to reduce CVD risk amongst these conditions share a 
common theme, with the use of disease-modifying anti-
inflammatory medications paramount to all.  
ABBREVIATIONS 
RA =  Rheumatoid  arthritis 
SLE =  Systemic  lupus  erythematosus 
CVD =  Cardiovascular  disease 
LDL =  Low-density  lipoprotein 
APS =  Anti-phospholipid  syndrome 
PSS  =  Primary Sjogrens syndrome 
SSc =  Systemic  sclerosis 
NO =  Nitric  oxide 
eNOS  =  Endothelial nitric oxide synthase 
TG =  Triglyceride 
Lp(a) =  Lipoprotein  (a) 
OxLDL =  Oxidised  low-desnsity  lipoproteins 
ApoB =  ApolipoproteinB 
HDL =  High-desnity  lipoproteins 














Fig. (5). Common changes in the lipid profile amongst the autoimmune rheumatic disease and their impact on atherosclerotic plaque 
formation. LDL: Low density lipoproteins, TG: Triglycerides, Lp(a): Lipoprotein (a), Anti-LPL: anti-Lipoprotein Lipase, HDL: high density 
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GC =  Glucocorticoids 
NHANES  =  National Health and Nutrition Examination 
survey 
ApoA1 =  Apolipoprotein  A1 
PAI-1  =  Plasminogen activator inhibitor 
CRP  =  C reactive protein 
TC =  Total  cholesterol 
TNF  =  Tumour necrosis factor 
IL =  Interleukin 
ROS  =  Reactive oxygen species 
LPL =  Lipoprotein  lipase 
NMR =  Nuclear  magnetic  resonance 
DsDNA  =  Double stranded DNA 
ESR  =  Erythrocyte sedimentation rate 
IMT =  Intima-media  thickness 
HCQ =  Hydroxychloroquine 
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